Head and neck cancers: an insight into the current studies
What to do with BRAF-mutant melanoma patients who have a poor prognosis?
Using biomarkers to predict response to combination therapies in BRAF-mutant melanoma
Blocking C-MET and BRAF pathways in melanoma to overcome resistance in mouse models
Combining agents to improve response rates in genitourinary cancer
Andrea B. Apolo